At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)
In Brief
A Phase 2 clinical trial evaluating Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, and 16 other interventions for Acute Lymphoblastic Leukemia and 6 related conditions. Active but no longer recruiting, targeting 97 participants across 157 sites.
Signals
Detailed Summary
This phase II trial is studying the side effects of giving combination chemotherapy together with or without donor stem cell transplant and to see how well it works in treating patients with acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect).
Study Details
Timeline
Arms & Interventions
See Detailed Description
Interventions
Undergo allogeneic stem cell transplant
Given IV
Given IT
Given PO
Given IV or PO
Given IV
Given IV
Given SC
Correlative studies
Given IV
Given IV or IT
Given IV
Undergo allogeneic stem cell transplant
Given PO
Given PO
Given IV
Undergo TBI
Given IV